Ucello is a universal chimeric antigen receptor T cell company focused on the next generation cell therapy
Location: China, Sichuan, Chengdu City
Total raised: $25M
Investors 2
| Date | Name | Website |
| 09.02.2022 | Matrix Par... | matrixpart... |
| 19.03.2022 | Northern L... | nlvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.02.2022 | Series A | $25M | - |
Mentions in press and media 3
| Date | Title | Description |
| 14.02.2022 | Ucello Therapeutics Closes US$25M Series A Financing | Ucello Therapeutics, a San Diego, CA and Chengdu, China-based biotechnology company developing universal CAR-T therapies, raised US$25M in Series A funding. The round was led by Matrix Partners China with participation form Co-Win Ventures,... |
| 11.02.2022 | Ucello Therapeutics Gets $25M | San Diego- and Chengdu, China-based Ucello Therapeutics, a biotechnology startup which says it is developing universal CAR-T therapies, has raised $25M in a Series A financing round. The company said the funding was led by Matrix Partners C... |
| 11.02.2022 | Ucello Therapeutics Completes US$25 Million Series A Financing | SAN DIEGO, Calif. and CHENGDU, China, Feb. 11, 2022 /PRNewswire/ -- Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of a US$25 million Series A fina... |